Silence Therapeutics And Quark Pharmaceuticals Expand Strategic Licensing Agreement.
Silence Therapeutics plc and Quark Pharmaceuticals, Inc., announced an expansion of their current strategic technology licensing agreement.
In April 2005 the companies signed an Option and Licence Agreement, which provided Quark with access to Silence Therapeutics' novel proprietary siRNA technology, AtuRNAi. The first outcome of the companies' relationship was the development of the AtuRNAi technology-based compound RTP801i, which was licensed to Pfizer Inc in 2006 by Quark and is currently in a phase 1 clinical trial in patients with wet age related macular degeneration. Quark's product portfolio includes one additional siRNA molecule with a structure covered by patents licensed from Silence Therapeutics.
The expanded agreement provides Quark with options to non-exclusive licenses to develop additional molecules against 3 specific targets using Silence Therapeutics' proprietary AtuRNAi technology. The terms of the amendment will entitle Silence Therapeutics to milestone payments and a royalty on product sales after exercise of the options by Quark. Further financial details were not disclosed.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.